1,403,881 2,341,108 4,380,219 6,669,038
Net gain from
litigation
settlement - - - (40,170,000)
--- --- --- -----------
Total operating
expenses 6,555,709 5,663,368 17,672,248 (23,760,655)
--------- --------- ---------- -----------
Income (loss) from
operations (538,111) (999,003) 7,095,518 39,756,159
Investment income 473,069 759,511 1,520,890 1,382,778
Interest expense (1,266) (2,451) (2,287) (7,353)
------ ------ ------ ------
Income (loss)
before income taxes (66,308) (241,943) 8,614,121 41,131,584
Income tax
(benefit) provision (84,690) - 174,855 827,471
------- --- ------- -------
Net income (loss) $18,382 $(241,943) $8,439,266 $40,304,113
======= ========= ========== ===========
Earnings (loss) per share:
Basic $- $(0.01) $0.27 $1.31
=== ====== ===== =====
Diluted $- $(0.01) $0.27 $1.29
=== ====== ===== =====
Weighted average
shares outstanding:
Basic 30,809,445 30,953,608 31,043,093 30,763,049
========== ========== ========== ==========
Diluted 31,024,685 30,953,608 31,395,551 31,238,013
========== ========== ========== ==========
December 31, March 31,
Balance Sheet Da
'/>"/>SOURCE Repligen Corporation Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related biology technology :1.
Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST2.
Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results3.
Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST4.
Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT5.
Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model6.
Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program7.
Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results8.
Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results9.
Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit10.
Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results11.
Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results